Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
E. G. Shuldiner, S. Karmakar, M. K. Tsai, J. D. Hebert, Y. J. Tang, L. Andrejka, M. Wang, C. R. Detrick, H. Cai, R. Tang, D. A. Petrov, M. M. Winslow
This study shows aging suppresses lung tumor initiation and growth in mice, with age-dependent effects on tumor suppressor genes like PTEN and persistent age-related transcriptomic changes in tumors.
bioRxiv · May 28, 2024 · PreprintCancer Biology
J. D. Hebert, H. Xu, Y. J. Tang, P. A. Ruiz, C. R. Detrick, J. Wang, N. W. Hughes, O. Donosa, L. Andrejka, S. Karmakar, I. Aboiralor, R. Tang, J. Sage, L. Cong, D. Petrov, M. M. Winslow
This study develops transgenic Cas12a mice to enable efficient, multiplexed somatic genome editing for studying complex genetic interactions in vivo.
bioRxiv · Mar 7, 2024Cancer Biology
J. D. Hebert, Y. J. Tang, L. Andrejka, S. S. Lopez, D. A. Petrov, G. Boross, M. M. Winslow
The paper uses in vivo genome editing to study genetic interactions in lung cancer, finding widespread negative epistasis among tumor suppressor genes.
bioRxiv · Mar 7, 2024 · PreprintCancer Biology
M. Yousefi, L. Andrejka, M. M. Winslow, D. A. Petrov, G. Boross
This study characterizes the fitness landscapes of tumor suppressor genes in oncogene-negative lung adenocarcinoma, finding that multiple mutations can drive tumor growth with minimal constraints on mutational order.
bioRxiv · Jan 30, 2023Cancer Biology
M. C. Lee, H. Cai, C. W. Murray, C. Li, Y. T. Shue, L. Andrejka, A. L. He, A. Holzem, A. P. Drainas, J. H. Ko, G. L. Coles, C. Kong, S. Zhu, C. Zhu, J. Wang, , J. Sage
The paper develops a multiplexed in vivo approach to identify driver genes in SCLC using CRISPR/Cas9 and lentiviral barcoding, finding TSC1 as a robust tumor suppressor.
bioRxiv · Mar 28, 2022Cancer Biology
M. Yousefi, G. Boross, C. Weiss, C. W. Murray, J. D. Hebert, H. Cai, E. L. Ashkin, S. Karmakar, L. Andrejka, L. Chen, M. Wang, M. K. Tsai, W.-Y. Lin, C. Li, P. Yakhchalian, , M. M. Winslow
This study identifies RAS/PI3K pathway activation as a common driver in oncogene-negative lung adenocarcinomas and shows these tumors are vulnerable to targeted therapy.
bioRxiv · Oct 20, 2021Cancer Biology
R. Tang, E. G. Shuldiner, M. Kelly, C. W. Murray, J. D. Hebert, L. Andrejka, M. K. Tsai, N. W. Hughes, M. I. Parker, H. Cai, Y.-C. Li, G. Wahl, R. Dunbrack, P. K. Jackson, D. Petrov, M. M. Winslow
This study identifies HRAS and NRAS as suppressors of KRASG12D-driven lung cancer using CRISPR screens in mouse models and confirms their role in human cell lines.
bioRxiv · Jul 8, 2021 · PreprintCancer Biology
G. Foggetti, C. Li, H. Cai, J. Hellyer, W.-Y. Lin, D. Ayeni, K. Hastings, J. Choi, A. Wurtz, L. Andrejka, D. Maghini, N. Rashleigh, S. Levy, R. Homer, S. Gettinger, , K. Politi
This study investigates how genetic alterations affect EGFR-driven lung cancer growth and therapy response using a mouse model and CRISPR-Cas9 editing.
Cancer Discovery · Mar 11, 2021Peer-reviewedCancer Biology